Eating Disorders
... improvement in eating disorder psychopathology at end of treatment. For adolescents whose mothers expressed any hostility, however, AFT was associated with greater gains in expected body weight compared with FBT. At the end of treatment, family functioning was better for families whose mother expres ...
... improvement in eating disorder psychopathology at end of treatment. For adolescents whose mothers expressed any hostility, however, AFT was associated with greater gains in expected body weight compared with FBT. At the end of treatment, family functioning was better for families whose mother expres ...
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I
... oils and soap substitutes should also be used. In winter time more lipid ingredients are preferable (3b, C). A regular use of emollient has a short- and long-term steroid sparing effect in mild to moderate AE. An induction of remission with topical corticosteroids is required first (2a, B). The rapi ...
... oils and soap substitutes should also be used. In winter time more lipid ingredients are preferable (3b, C). A regular use of emollient has a short- and long-term steroid sparing effect in mild to moderate AE. An induction of remission with topical corticosteroids is required first (2a, B). The rapi ...
Guidelines for treatment of atopic eczema
... oils and soap substitutes should also be used. In winter time more lipid ingredients are preferable (3b, C). A regular use of emollient has a short- and long-term steroid sparing effect in mild to moderate AE. An induction of remission with topical corticosteroids is required first (2a, B). The rapi ...
... oils and soap substitutes should also be used. In winter time more lipid ingredients are preferable (3b, C). A regular use of emollient has a short- and long-term steroid sparing effect in mild to moderate AE. An induction of remission with topical corticosteroids is required first (2a, B). The rapi ...
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I GUIDELINES
... oils and soap substitutes should also be used. In winter time more lipid ingredients are preferable (3b, C). A regular use of emollient has a short- and long-term steroid sparing effect in mild to moderate AE. An induction of remission with topical corticosteroids is required first (2a, B). The rapi ...
... oils and soap substitutes should also be used. In winter time more lipid ingredients are preferable (3b, C). A regular use of emollient has a short- and long-term steroid sparing effect in mild to moderate AE. An induction of remission with topical corticosteroids is required first (2a, B). The rapi ...
A Stepwise Approach to Management of Stable
... related to atropine.22 Ipratropium is poorly absorbed into the circulation from either the nasal mucosa or from the airway, and its half-life of elimination is about 1.6 hours after inhalation administration.21,25 Ipratropium is a nonselective antagonist of M1, M2, and M3 receptors. The blockade of ...
... related to atropine.22 Ipratropium is poorly absorbed into the circulation from either the nasal mucosa or from the airway, and its half-life of elimination is about 1.6 hours after inhalation administration.21,25 Ipratropium is a nonselective antagonist of M1, M2, and M3 receptors. The blockade of ...
Guideline Summary NGC-9333
... The age range for this guideline was 12 years and over. Studies that included people younger than 12 were included only if the mean age of the population was over 12 years. Crossover trials were only included in the review questions for acute treatment, however they were only included if it was clea ...
... The age range for this guideline was 12 years and over. Studies that included people younger than 12 were included only if the mean age of the population was over 12 years. Crossover trials were only included in the review questions for acute treatment, however they were only included if it was clea ...
Lucentis : EPAR - Scientific Discussion
... factor (VEGF) is considered critical both in physiological and in pathological angiogenesis, such as in AMD. Even though overexpression of VEGF is not likely to be the sole factor behind AMD, elevated levels of VEGF have been found in pathological neovascularisation, both in experimental models and ...
... factor (VEGF) is considered critical both in physiological and in pathological angiogenesis, such as in AMD. Even though overexpression of VEGF is not likely to be the sole factor behind AMD, elevated levels of VEGF have been found in pathological neovascularisation, both in experimental models and ...
Protocol S1.
... Patients will have study visits every two weeks during the first 2 months of therapy. At each study visit, there will be a clinical assessment for toxicity and a sputum specimen will be obtained for smear and culture (two sputum specimens will be obtained after 8-weeks). Mycobacterial cultures must ...
... Patients will have study visits every two weeks during the first 2 months of therapy. At each study visit, there will be a clinical assessment for toxicity and a sputum specimen will be obtained for smear and culture (two sputum specimens will be obtained after 8-weeks). Mycobacterial cultures must ...
L-Tyrosine Monograph - Alternative Medicine Review
... exposure to 71°F/22°C and 550 meters simulated altitude (normal control) for 4.5 hours. Forty minutes after stress initiation subjects received a second 50 mg/kg dose of tyrosine or placebo. At the end of the stress period, tyrosine administration had significantly reduced headache, coldness, stress ...
... exposure to 71°F/22°C and 550 meters simulated altitude (normal control) for 4.5 hours. Forty minutes after stress initiation subjects received a second 50 mg/kg dose of tyrosine or placebo. At the end of the stress period, tyrosine administration had significantly reduced headache, coldness, stress ...
Extract from the Clinical Evaluation Report for Empagliflozin
... Type 2 diabetes mellitus (T2DM) is characterised by insulin resistance and impaired insulin secretion. Diabetes is also associated with microvascular complications and elevated cardiovascular risk. The estimated worldwide prevalence of diabetes is 366 million with an increase of 50 % expected within ...
... Type 2 diabetes mellitus (T2DM) is characterised by insulin resistance and impaired insulin secretion. Diabetes is also associated with microvascular complications and elevated cardiovascular risk. The estimated worldwide prevalence of diabetes is 366 million with an increase of 50 % expected within ...
GUIDELINE FOR GOOD CLINICAL PRACTICE
... lack of comparisons with an especially relevant active comparator, or absence of information on some patient populations, on pertinent endpoints, or on use in combination therapy). ...
... lack of comparisons with an especially relevant active comparator, or absence of information on some patient populations, on pertinent endpoints, or on use in combination therapy). ...
Maintenance treatment of bipolar disorders
... On the other hand, rating scales used in studies are not uniform which creates the “Tower of Babel” problem. The content overlap with the MADRS and the YMRS, for instance, might in themselves be a source of bias. To increase the content validity of different scales, e.g., MADRS and HAM-D some acute ...
... On the other hand, rating scales used in studies are not uniform which creates the “Tower of Babel” problem. The content overlap with the MADRS and the YMRS, for instance, might in themselves be a source of bias. To increase the content validity of different scales, e.g., MADRS and HAM-D some acute ...
Lyrica : EPAR - Scientific Discussion
... patient at onset. Both aetiology (idiopathic, symptomatic and cryptogenic) and localization (partial vs generalised) are considered crucial prerequisites for an adequate approach of epileptic disorders. The debate on these topics is still ongoing. In the case of partial seizures, there is always a f ...
... patient at onset. Both aetiology (idiopathic, symptomatic and cryptogenic) and localization (partial vs generalised) are considered crucial prerequisites for an adequate approach of epileptic disorders. The debate on these topics is still ongoing. In the case of partial seizures, there is always a f ...
Nasacort® AQ (triamcinolone acetonide)
... as opposed to physiologic doses suggests that rodents are more prone to teratogenic effects from corticosteroids than humans. In addition, because there is a natural increase in glucocorticoid production during pregnancy, most women will require a lower exogenous corticosteroid dose and many will no ...
... as opposed to physiologic doses suggests that rodents are more prone to teratogenic effects from corticosteroids than humans. In addition, because there is a natural increase in glucocorticoid production during pregnancy, most women will require a lower exogenous corticosteroid dose and many will no ...
HEMORRHOIDS – A COMMON AILMENT AMONG ADULTS, CAUSES & TREATMENT:... Review Article BHARAT GAMI
... venous tone, a positive step for hemorrhoid treatments96, 97. Bennani et al carried out open-label multicentrer study with 124 patients and 69 % of efficacy of plant as antihemorrhoidal was found98. Patients treated with butcher’s broom were show statistically significant improvement in a variety of ...
... venous tone, a positive step for hemorrhoid treatments96, 97. Bennani et al carried out open-label multicentrer study with 124 patients and 69 % of efficacy of plant as antihemorrhoidal was found98. Patients treated with butcher’s broom were show statistically significant improvement in a variety of ...
Substitution Treatment in European Prisons
... are over-represented in prisons. In these regions they represent about one third of the prison population and up to 80% in some countries such as in Central Asia. In subSaharan Africa, the problem is emerging, while in Latin America, cocaine use is more frequent. Prisons are not the right place for ...
... are over-represented in prisons. In these regions they represent about one third of the prison population and up to 80% in some countries such as in Central Asia. In subSaharan Africa, the problem is emerging, while in Latin America, cocaine use is more frequent. Prisons are not the right place for ...
THE TREATMENT OF SYMPTOMATIC OSTEOPOROTIC SPINAL COMPRESSION FRACTURES GUIDELINE AND EVIDENCE REPORT
... This Clinical Practice Guideline was developed by an AAOS physician volunteer Work Group based on a systematic review of the current scientific and clinical information and accepted approaches to treatment and/or diagnosis. This Clinical Practice Guideline is not intended to be a fixed protocol, as ...
... This Clinical Practice Guideline was developed by an AAOS physician volunteer Work Group based on a systematic review of the current scientific and clinical information and accepted approaches to treatment and/or diagnosis. This Clinical Practice Guideline is not intended to be a fixed protocol, as ...
American Urological Association (AUA) Guideline DIAGNOSIS AND TREATMENT OF
... 5. Initial treatment type and level should depend on symptom severity, clinician judgment, and patient preferences; appropriate entry points into the treatment portion of the algorithm depend on these factors. Clinical Principle 6. Multiple, simultaneous treatments may be considered if it is in the ...
... 5. Initial treatment type and level should depend on symptom severity, clinician judgment, and patient preferences; appropriate entry points into the treatment portion of the algorithm depend on these factors. Clinical Principle 6. Multiple, simultaneous treatments may be considered if it is in the ...
Explanation and elaboration document (WORD, 855KB)
... formatted as “hidden Text” that will not show in printing). Section headings and template text formatted in regular type red gives you reference to the legal requirements. This text may be deleted. Section headings and template text formatted in regular type (black) should be included in your protoc ...
... formatted as “hidden Text” that will not show in printing). Section headings and template text formatted in regular type red gives you reference to the legal requirements. This text may be deleted. Section headings and template text formatted in regular type (black) should be included in your protoc ...
New Drug Approvals – 2007
... (most of the population) and at doses ≤10mg, nebivolol is preferentially beta-1 Heart Disease hypertension. selective. In poor metabolizers and at higher doses, nebivolol inhibits both and Stroke May be receptors. It also has vasodilating properties. Statistics 2006, used alone or nearly one in in c ...
... (most of the population) and at doses ≤10mg, nebivolol is preferentially beta-1 Heart Disease hypertension. selective. In poor metabolizers and at higher doses, nebivolol inhibits both and Stroke May be receptors. It also has vasodilating properties. Statistics 2006, used alone or nearly one in in c ...
A randomised phase IIb trial of BEvACizumab added to
... Blood pressure below 95 centile for age and sex. Use of antihypertensive medication is permitted Males or females of reproductive potential may not participate unless they agree to use an adequate method of birth control, i.e. with a failure rate of less than 1% per year, (e.g. implants, injectables ...
... Blood pressure below 95 centile for age and sex. Use of antihypertensive medication is permitted Males or females of reproductive potential may not participate unless they agree to use an adequate method of birth control, i.e. with a failure rate of less than 1% per year, (e.g. implants, injectables ...
Prozac - Eli Lilly and Company
... Adult — Initiate PROZAC 20 mg/day orally in the morning. Consider a dose increase after several weeks if insufficient clinical improvement is observed. Administer doses above 20 mg/day once daily in the morning or twice daily (i.e., morning and noon).The maximum fluoxetine dose should not exceed 80 ...
... Adult — Initiate PROZAC 20 mg/day orally in the morning. Consider a dose increase after several weeks if insufficient clinical improvement is observed. Administer doses above 20 mg/day once daily in the morning or twice daily (i.e., morning and noon).The maximum fluoxetine dose should not exceed 80 ...
Cymbalta - Eli Lilly and Company
... Adults — For most patients, initiate CYMBALTA 60 mg once daily. For some patients, it may be desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to the medication before increasing to 60 mg once daily. While a 120 mg once daily dose was shown to be effective, there is no e ...
... Adults — For most patients, initiate CYMBALTA 60 mg once daily. For some patients, it may be desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to the medication before increasing to 60 mg once daily. While a 120 mg once daily dose was shown to be effective, there is no e ...
1
... Adults — For most patients, initiate CYMBALTA 60 mg once daily. For some patients, it may be desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to the medication before increasing to 60 mg once daily. While a 120 mg once daily dose was shown to be effective, there is no e ...
... Adults — For most patients, initiate CYMBALTA 60 mg once daily. For some patients, it may be desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to the medication before increasing to 60 mg once daily. While a 120 mg once daily dose was shown to be effective, there is no e ...
Treatment for Restless Legs Syndrome Comparative Effectiveness Review Number 86
... Evidence Reports/Technology Assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care. The EPCs now lend their expertise to the Effective Health Care Program by conducting comparative effectiveness reviews (CERs) of medications, devices, an ...
... Evidence Reports/Technology Assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care. The EPCs now lend their expertise to the Effective Health Care Program by conducting comparative effectiveness reviews (CERs) of medications, devices, an ...
Placebo-controlled study
Placebo-controlled studies are a way of testing a medical therapy in which, in addition to a group of subjects that receives the treatment to be evaluated, a separate control group receives a sham ""placebo"" treatment which is specifically designed to have no real effect. Placebos are most commonly used in blinded trials, where subjects do not know whether they are receiving real or placebo treatment. Often, there is also a further ""natural history"" group that does not receive any treatment at all.The purpose of the placebo group is to account for the placebo effect, that is, effects from treatment that do not depend on the treatment itself. Such factors include knowing one is receiving a treatment, attention from health care professionals, and the expectations of a treatment's effectiveness by those running the research study. Without a placebo group to compare against, it is not possible to know whether the treatment itself had any effect.Patients frequently show improvement even when given a sham or ""fake"" treatment. Such intentionally inert placebo treatments can take many forms, such as a pill containing only sugar, a surgery where nothing efficacious is actually done (just an incision and sometimes some minor touching or handling of the underlying structures), or a medical device (such as an ultrasound machine) that is not actually turned on. Also, due to the body's natural healing ability and statistical effects such as regression to the mean, many patients will get better even when given no treatment at all. Thus, the relevant question when assessing a treatment is not ""does the treatment work?"" but ""does the treatment work better than a placebo treatment, or no treatment at all?"" As one early clinical trial researcher wrote, ""the first object of a therapeutic trial is to discover whether the patients who receive the treatment under investigation are cured more rapidly, more completely or more frequently, than they would have been without it.""p.195 More broadly, the aim of a clinical trial is to determine what treatments, delivered in what circumstances, to which patients, in what conditions, are the most effective.Therefore, the use of placebos is a standard control component of most clinical trials, which attempt to make some sort of quantitative assessment of the efficacy of medicinal drugs or treatments. Such a test or clinical trial is called a placebo-controlled study, and its control is of the negative type. A study whose control is a previously tested treatment, rather than no treatment, is called a positive-control study, because its control is of the positive type.Government regulatory agencies approve new drugs only after tests establish not only that patients respond to them, but also that their effect is greater than that of a placebo (by way of affecting more patients, by affecting responders more strongly, or both). As a result, ""placebo-controlled studies often are designed in such a way that disadvantages the placebo condition"".